-
Mashup Score: 14
Patients with ALK-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy and pharmacokinetics of deulorlatinib in ALK-positive NSCLC.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 154COVID-19 vaccines: history of the pandemic's great scientific success and flawed policy implementation - PubMed - 4 hour(s) ago
The COVID-19 vaccine has been a miraculous, life-saving advance, offering staggering efficacy in adults, and was developed with astonishing speed. The time from sequencing the virus to authorizing the first COVID-19 vaccine was so brisk even the optimists appear close-minded. Yet, simultaneously, Un …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
A little more complicated and I explain in link but yes, Pfizer changed statistical analysis plan to delay the result till post election. This has no scientific basis, and delayed deployment by 2 critical weeks in 2020 with many dead as a result https://t.co/byHZpWaeCI https://t.co/n5WDzaY87t
-
-
Mashup Score: 2Development of a fibrin-targeted theranostic for gastric cancer - 4 hour(s) ago
Fibrin within the tumor can be used as a target for the detection and treatment of gastric cancer.
Source: www.science.orgCategories: General Medicine News, Hem/OncsTweet-
Cool paper from @ShadiEsfahani and team in @ScienceTM @MGHCancerCenter Development of a fibrin-targeted theranostic for gastric cancer | Science Translational Medicine https://t.co/kCcmKJjvaB
-
-
Mashup Score: 1Nurses Empower Change Through Leadership and Advocacy Roles | Oncology Nursing Society - 5 hour(s) ago
Oncology nurses are using their clinical expertise and voice to advocate for policy change, improve patient care, and shape the future of healthcare leadership. In the dynamic world of oncology nursing, leadership can often be a byproduct of traditional clinical roles. Nurses in direct care can use their clinical experience to shape policies, advocate for patients, and influence workplace improvements. “I have learned the power that nurses have as a collective group to advocate for change,” ONS member
Source: www.ons.orgCategories: General Medicine News, Hem/OncsTweet-
“Oncology nurses are using their clinical expertise and voice to advocate for policy change, improve patient care, and shape the future of healthcare leadership” Nurses Empower Change Through Leadership and Advocacy Roles @oncologynursing https://t.co/KIrEibIhsB
-
-
Mashup Score: 2Job Advert - 5 hour(s) ago
Skip to main content We’ ve put some small files called cookies on your device to help us make improvements to our site. To improve our site we’ d also like to use cookies which will send information to Google Analytics. You can read more about our cookies before you choose. BETA Your feedback will help us to improve this service. We are looking to appoint a Whole time Consultant Haematologist with a specialist interest in Haemostasis and Thrombosis within Sheffield Teaching Hospitals NHS Foundation
Source: beta.jobs.nhs.ukCategories: General Medicine News, Hem/OncsTweet-
Are you looking for a permanent post as a consultant in haemostasis and thrombosis in a top department? The Sheffield Haemophilia and Thrombosis Centre has a position available. https://t.co/WkyzJVlNvq
-
-
Mashup Score: 2Project Facilitate: 5 Years of Progress, Outreach, and Service - 5 hour(s) ago
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the FDA. In this installment, the authors discuss the past 5 years of Project Facilitate, an OCE in…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
Project Facilitate: 5 Years of Progress, Outreach, and Service - The ASCO Post https://t.co/f0asnGSUnY
-
-
Mashup Score: 1Subscribe here - 6 hour(s) ago
Get started today before this once in a lifetime opportunity
Source: www.yourpathinfocus.comCategories: General Medicine News, Hem/OncsTweet-
Follow for updates, news, behind the scenes, & podcast by subscribing here❤️: https://t.co/6kDOpcWAIV
-
-
Mashup Score: 9INDEPSO-ISPSM Consensus on Peritoneal Malignancies: Management of Colorectal Peritoneal Metastases | JCO Global Oncology - 7 hour(s) ago
PURPOSEThis manuscript reports the results of the Indian Network for Development of Peritoneal Surface Oncology and Indian Society of Peritoneal Surface Malignancies (INDEPSO-ISPSM) consensus that aimed to provide recommendations for some important …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @Erman_Akkus: 📘Management of colorectal peritoneal metastases @JCOGO_ASCO 🟠Indian consensus statement 👉https://t.co/Oq1aG1qae4 @ASC…
-
-
Mashup Score: 14Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma - 8 hour(s) ago
Bone Marrow Transplantation – Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
🎉Finally out🎉 Tandem transplant should be reserved to myeloma patients with sub-optimal responses to induction therapy AND a first transplant Congrats Max Merz and team @BMTjournal #mmsm https://t.co/uuVb1taUDh
-
-
Mashup Score: 1UPHS releases sweeping Climate and Sustainability Action Plan - 8 hour(s) ago
The plan outlines an ambitious roadmap to become the nation’s most eco-friendly health care organization.
Source: www.pennmedicine.orgCategories: General Medicine News, Hem/OncsTweet-
Penn Medicine has launched its first-ever Climate and Sustainability Action Plan with a goal to cut emissions in half by 2030 and achieve carbon neutrality by 2042. #PennMedicineProud https://t.co/Sy9O1o4qZy
-
Phase I study of next-gen #ALK #ROS1 TKI deulorlatinib @JTOonline. AEs include lipids & weight gain; 1.5% d/c for AE. Deulorlatinib 60mg in ALK: 1L RR 88%, icRR 75%, DOR NR. Post 2G TKI, RR 38%, icRR 70%, DOR NR. Post crizotinib RR 71%, DOR 18m. https://t.co/LJIcCYKGG4